The shares of the Spanish pharmaceutical company Rovi plummeted 20% this Monday around 11:00 a.m., until they were exchanged at a price of 47.25 euros, given the formal investigation that is underway to establish whether there is any connection between Moderna’s vaccine. against Covid-19 and two deaths in Japan.
The company has assured the National Securities Market Commission (CNMV) that, to date, there is no evidence that these deaths have been caused by the vaccine.
Rovi has affirmed that it will continue to proactively collaborate in the investigation into the appearance of particles in Moderna vaccine vials distributed in Japan, in whose production process the Spanish company participates.
The firm has explained that the formal investigation is continuing to determine what happened in the filling and finishing process of the corresponding batch.
“As the laboratory that owns the vaccine, Moderna, and the company responsible for the distribution of the vaccine in Japan, Takeda, have publicly reported, there has been, unfortunately, the death of two people who had received the vaccine for Covid -19 of Moderna in Japan of the aforementioned batch, “he explained.
“As recently reported, the detection of particles in some vials of product batches distributed in Japan is an event that is in the process of being investigated by Rovi, in coordination with Moderna, Takeda and the health authorities,” he added. .
Thus, Rovi will continue with the investigation of this issue, pending its completion and the publication of the conclusions by Moderna and Takeda, which will be reported in due course.
The Japanese health authorities and the Madrid pharmaceutical company are conducting respective investigations into the impurities found in several vials of Moderna COVID-19 vaccines manufactured in Spain, some of which, apparently, come from the bottle caps. Japan decided last Thursday to block 1.63 million doses of Moderna manufactured in a Spanish plant as a precautionary measure, after “foreign substances” were found in 39 vials (bottles containing 10 doses), according to the Ministry of Health. . That day, the price of Rovi already sank more than 13%.
The 1.63 million doses whose use was suspended had been distributed for application in five Japanese prefectures (Ibaraki, Saitama, Tokyo, Gifu and Aichi), corresponding to three batches of the vaccines and of them around half a million had been already inoculated.
The Government also announced on Saturday that it is investigating the death of two people who were vaccinated with one of the three batches of Moderna before being withdrawn, to try to clarify if they are connected with the inoculation, although at the moment it is unknown “if there are relationship “between deaths and vaccination.
Meanwhile, Rovi pharmaceutical laboratories have reported this Monday that they are continuing the investigation to determine what happened in the “filling and finishing process” of those batches. “To date, there is no evidence that these deaths were caused by the vaccine. In any case, a formal investigation is underway to establish whether there is any connection,” the company says in a statement.
Rovi adds that it will continue to proactively collaborate in the investigation of this issue, pending its completion and the publication of the findings by Moderna and Takeda.